What's Going On With Tempus AI Stock Monday?

Benzinga_recent_news02-02

Tempus AI, Inc. (NASDAQ:TEM) stock fell Monday as Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced the completion of its one-millionth deoxyribonucleic acid (DNA)/ ribonucleic acid (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

才旦
02-04 01:34
才旦
為什麼

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608861213?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/02/Tempus-Logo-Displayed-On-Smartphone.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-02-02 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608861213","market":"sh","top_or_hot":-1,"title":"What's Going On With Tempus AI Stock Monday?","media":"Benzinga_recent_news","content":"<div>\n<p>Tempus AI, Inc. (NASDAQ:TEM) stock fell Monday as Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced the completion of its one-millionth deoxyribonucleic acid (DNA)/ ribonucleic acid (...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Tempus AI Stock Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Tempus AI Stock Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-02 21:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempus AI, Inc. (NASDAQ:TEM) stock fell Monday as Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced the completion of its one-millionth deoxyribonucleic acid (DNA)/ ribonucleic acid (...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4613","symbol_name":"AI应用软件","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2","article_id":"2608861213","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/02/Tempus-Logo-Displayed-On-Smartphone.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608861213","pubTimestamp":1770037380,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Ambry Genetics, a subsidiary of Tempus AI, announced completion of 1 million DNA/RNA tests for hereditary cancer and rare disease.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4613":"AI应用软件","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4023":"应用软件","BK4139":"生物科技","BK4587":"ChatGPT概念","BK4611":"AI医疗","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4121":"生命科学工具和服务","TEM":"Tempus AI","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4543":"AI","BK4217":"自存仓储房地产信托","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4109":"特种化学制品","BK4551":"寇图资本持仓","BK4528":"SaaS概念","BK4588":"碎股"},"translate_title":"周一Tempus AI股票发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1.98},"content_text":"Tempus AI, Inc. (NASDAQ:TEM) stock fell Monday as Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced the completion of its one-millionth deoxyribonucleic acid (DNA)/ ribonucleic acid (RNA) test, highlighting growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease. \nAmbry Genetics launched RNA testing commercially in 2019 as +RNAinsight. Data from over 450,000 patients showed that 1 in 25 positive patients would have been missed without RNA data. The data also showed RNA inclusion led to a 6% reduction in variants classified as uncertain.\nIn 2024, Ambry added RNA testing to its ExomeReveal offering for rare disease cases.\nTempus AI is currently trading 11.4% below its 20-day simple moving average (SMA) and 23% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased by 2.79% over the past 12 months and are positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the stock.\nThe RSI is at 37.98, which is considered neutral territory, while the MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.\nInvestors are looking ahead to the next earnings report on Feb. 23.\nAnalyst Consensus & Recent Actions:\nThe stock carries a Buy Rating with an average price target of $77.86. Recent analyst moves include:\nBelow is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market:\nTEM Price Action: Tempus AI shares were down 1.60% at $58.86 during premarket trading on Monday, according to Benzinga Pro data.\nPhoto by T. Schneider via Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":528866849768448,"gmtCreate":1770140059227,"gmtModify":1770148093124,"author":{"id":"4227195289931342","authorId":"4227195289931342","name":"才旦","avatar":"https://community-static.tradeup.com/news/99f3fc89c87e5d0c55ed276a6ee3f060","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"4227195289931342","idStr":"4227195289931342"},"htmlText":"為什麼","listText":"為什麼","text":"為什麼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/528866849768448","repostId":2608861213,"repostType":2,"repost":{"id":"2608861213","kind":"highlight","pubTimestamp":1770037380,"share":"https://ttm.financial/m/news/2608861213?lang=en_US&edition=fundamental","pubTime":"2026-02-02 21:03","market":"sh","language":"en","title":"What's Going On With Tempus AI Stock Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2608861213","media":"Benzinga_recent_news","summary":"Ambry Genetics, a subsidiary of Tempus AI, announced completion of 1 million DNA/RNA tests for hereditary cancer and rare disease.","content":"<div>\n<p>Tempus AI, Inc. (NASDAQ:TEM) stock fell Monday as Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced the completion of its one-millionth deoxyribonucleic acid (DNA)/ ribonucleic acid (...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Tempus AI Stock Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Tempus AI Stock Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-02 21:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempus AI, Inc. (NASDAQ:TEM) stock fell Monday as Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced the completion of its one-millionth deoxyribonucleic acid (DNA)/ ribonucleic acid (...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/02/Tempus-Logo-Displayed-On-Smartphone.jpeg?optimize=medium&dpr=2&auto=webp&width=240","relate_stocks":{"BK4613":"AI应用软件","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4023":"应用软件","BK4139":"生物科技","BK4587":"ChatGPT概念","BK4611":"AI医疗","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4121":"生命科学工具和服务","TEM":"Tempus AI","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4543":"AI","BK4217":"自存仓储房地产信托","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4109":"特种化学制品","BK4551":"寇图资本持仓","BK4528":"SaaS概念","BK4588":"碎股"},"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50296224/whats-going-on-with-tempus-ai-stock-monday-2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2608861213","content_text":"Tempus AI, Inc. (NASDAQ:TEM) stock fell Monday as Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced the completion of its one-millionth deoxyribonucleic acid (DNA)/ ribonucleic acid (RNA) test, highlighting growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease. \nAmbry Genetics launched RNA testing commercially in 2019 as +RNAinsight. Data from over 450,000 patients showed that 1 in 25 positive patients would have been missed without RNA data. The data also showed RNA inclusion led to a 6% reduction in variants classified as uncertain.\nIn 2024, Ambry added RNA testing to its ExomeReveal offering for rare disease cases.\nTempus AI is currently trading 11.4% below its 20-day simple moving average (SMA) and 23% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased by 2.79% over the past 12 months and are positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the stock.\nThe RSI is at 37.98, which is considered neutral territory, while the MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.\nInvestors are looking ahead to the next earnings report on Feb. 23.\nAnalyst Consensus & Recent Actions:\nThe stock carries a Buy Rating with an average price target of $77.86. Recent analyst moves include:\nBelow is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market:\nTEM Price Action: Tempus AI shares were down 1.60% at $58.86 during premarket trading on Monday, according to Benzinga Pro data.\nPhoto by T. Schneider via Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","news_type":1,"symbols_score_info":{"TEM":1.98}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608861213","isCrawlerRequest":true}